Connect with us

Artificial Intelligence

Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology

GlobeNewswire

Published

on

CHICAGO, May 30, 2020 (GLOBE NEWSWIRE) — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of offerings designed to both advance vital research and support physicians in treating cancer patients, despite the challenges of the COVID-19 pandemic. Tempus is equipping physicians with the tools they need to treat high-risk patients while limiting their exposure to the virus, with mobile phlebotomy services, on-demand virtual case reviews, and COVID-19 PCR diagnostic testing for cancer patients.
“Cancer continues to be among the leading causes of death worldwide, and now more than ever, it is critical that cancer patients continue to receive the care and treatment they need for survival despite the pandemic,” said Eric Lefkofsky, Founder and CEO. “In the last few months, we’ve quickly mobilized to create offerings that ease the burden on physicians treating cancer patients amidst the threat of COVID-19, through a series of services and tests that are badly needed to ensure therapies aren’t disrupted.”COVID-19 PCR Diagnostic Testing
Earlier this month, Tempus launched a diagnostic polymerase chain reaction (PCR) test for COVID-19. Tempus’ CAP-accredited/CLIA-certified labs in Chicago and Atlanta are supporting the acceleration of testing in the U.S., and expect to test approximately 12,000 patients daily across both labs, with the ability to scale further if needed. Tempus makes it seamless for physicians to test their patients for the virus, providing results within 24-48 hours at no cost to the patient as Tempus bills insurance directly.  
Mobile Phlebotomy
Tempus now offers mobile phlebotomy services, which are available to patients who require a blood draw but are too sick or unable to travel to the clinic, or do not have access to an in-office phlebotomist or draw site. Experts are able to perform blood draws in patients’ homes for any Tempus test in which a blood sample is required, at no added cost.
Virtual Case Reviews
Tempus’ on-demand virtual case review system provides clinical support to physicians and care teams in a timely manner when an in-person meeting isn’t possible. Tempus’ Medical Affairs team is available to answer patient report questions in real-time in a secure portal.   In addition, Tempus now offers a variety of tele-health support services specific to COVID-19 if needed.
Research Collaboration
Tempus has launched a large research collaboration to structure data for up to 50,000 COVID-19 positive patients.  As part of the IRB approved study, Tempus is partnering with providers to collect data on COVID-19 patients, which Tempus is structuring and de-identifying without cost.  In addition, Tempus expects to perform full transcriptomic profiling of approximately 10,000 patients within the cohort. All data will be shared with all participating institutions without restriction. 
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Erin Carron
communications@tempus.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

GENFIT: Enhances Board of Directors with Two Strategic Appointments

GlobeNewswire

Published

on

Lille (France), Cambridge (Massachusetts, United States), July 7, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced, following its annual Shareholders Meeting,  the appointment of Ms. Katherine Kalin and Mr. Eric Baclet to the company’s Board of Directors. Together, they bring more than 50 years of combined pharmaceutical experience and deep subject matter expertise that will aid in the next phase of Genfit’s growth.Pascal Prigent, CEO of GENFIT, noted: “We are delighted to announce the appointments of Katherine and Eric to the board. Both bring a wealth of highly relevant life science industry experience. Ms. Kalin has extensive strategic and financial management experience in both pharmaceutical and diagnostic solutions, with a deep understanding of the U.S. market. Mr. Baclet has a broad experience covering therapeutic drug development, as well as commercial management in several markets, including China. Both will bring strong knowledge bases and strategic insights as the company works to determine the next corporate steps that will shape its transformation.”Ms. Kalin’s healthcare industry expertise spans diagnostics, medical devices, and pharmaceuticals. Ms. Kalin is currently a director on the boards of Clinical Genomics, a molecular diagnostic firm, Brown Advisory, a strategic advisory and investment firm, and Primari Analytics, a startup in artificial intelligence.  From 2012-17, Ms. Kalin led corporate strategy at Celgene, a global biopharmaceutical company, for 5 1/2 years. Prior to that, Ms. Kalin held executive leadership roles in marketing, sales, strategy and new business development at Johnson & Johnson (J&J) from 2002 to 2011. Prior to J&J, Ms. Kalin served as a Partner at McKinsey and Company, a global management consulting firm, where she negotiated and led consulting assignments, as a strategic advisor to pharmaceutical, medical device and other healthcare companies.Mr. Eric Baclet has over 30 years of experience with Eli Lilly in international drug development, management, and commercialization, all expertise he gained as President and General Manager of Lilly Italia, General Manager of Lilly China, VP of Global Marketing, and Executive Directorship of International Marketing, to name a few. Throughout his tenure at Eli Lilly, Mr. Baclet spearheaded international drug launches across multiple geographies, and led multi-disciplinary teams involved in biopharmaceutical value-chain management in more than seven countries.Jean-François Mouney, Chairman of the Board, added: “The Board is thrilled to welcome Katherine and Eric. We look forward to working with Pascal and the GENFIT team to help the company build value and succeed in its development programs in therapeutic areas with high unmet medical need.” ABOUT GENFITGENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. Its drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for NASH and GENFIT plans to initiate a Phase 3 clinical trial of elafibranor in patients with PBC. As part of GENFIT’s comprehensive approach to clinical management of patients with NASH, the Company is also developing a new, non-invasive blood-based diagnostic technology, NIS4™, which, if approved, could enable easier identification of patients with at-risk NASH. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 200 employees. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com
FORWARD LOOKING STATEMENTSThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including statements about the Company’s next development and transformation steps, its potential to create value, and new Directors’ contribution to value creation. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements.  Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates and the Company’s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the French Autorité des marchés financiers (“AMF”), including those listed in Section 2.1 “Main Risks and Uncertainties” of the Company’s 2019 Universal Registration Document filed with the AMF on May 27, 2020 under n° D.20-0503, which is available on GENFIT’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s 20-F dated May 27, 2020. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.  These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.CONTACTGENFIT | InvestorsNaomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com
PRESS RELATIONS | MediaHélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com
AttachmentGENFIT: Enhances Board of Directors with Two Strategic Appointments

Continue Reading

Artificial Intelligence

Second Front Systems Raises $6 Million to Provide Immediate Impact to National Security, led by ARTIS Ventures

GlobeNewswire

Published

on

San Francisco, CA, July 07, 2020 (GLOBE NEWSWIRE) — Second Front Systems, a software company working to disrupt the traditional aerospace and defense industry by acting as a beachhead for cutting-edge startups, today announced an oversubscribed $6 million in seed funding led by ARTIS Ventures. Additional investors include Kleiner Perkins, 8VC, Gula Tech Adventures, and Abstract VenturesThe venture funding will be used to expand the capabilities of Second Front’s software platform, Atlas Fulcrum, which has recently received a major contract award from the General Services Administration (GSA) and the Air Force’s AFWERX. The U.S. military recognizes that commercially driven tech, such as autonomy, cyber, biotech, and AI, has surpassed the defense base in relevance to national security in the 21st century. Acting as a “digital prime,” the Atlas Fulcrum platform empowers the U.S. government to regain control from the traditional defense industry in scouting, vetting, and securely fielding cutting-edge technology at scale.Austin Walne, partner at ARTIS Ventures will join Second Front’s board with General Peter Pace, former Chairman of the Joint Chiefs of Staff, General Stanley McChrystal, former commander of U.S. and international forces in Afghanistan, and Alberto Yepez, co-founder and managing director of ForgePoint Capital.
“The U.S. Military is actively seeking advances in artificial intelligence and synthetic biology. This aligns with ARTIS Ventures’ focus on the convergence of computer science and life science,” said Austin Walne, partner at ARTIS Ventures, whose firm is also an investor in Palantir. “Second Front’s executive team comes with proven military backgrounds, giving them an insider’s perspective on vetting and integrating technologies that will have an immediate impact on national security.” 
Second Front was started by former Marine Corps Major Peter Dixon, a scout sniper platoon commander who worked with In-Q-Tel and DARPA to pioneer counter-cartel and counter-insurgency technologies, including early adoption of Palantir, at the State Department and Pentagon, and retired Marine Corps Colonel Mark Butler, a fighter and test pilot who helped form the Marines’ arm of Cyber Command.
“I came back from combat deployments in Iraq and Afghanistan where my men and I were hamstrung by outdated technology that negated what should have been an advantage against insurgent adversaries,” said Second Front CEO Peter Dixon. “Subsequently, at the Pentagon, I watched as billions of dollars were awarded to traditional defense companies, many of whom were unable to deliver usable technology to front-line troops. This venture financing and initial partnerships gives Second Front the velocity to build a new type of ‘lean systems integrator’ that can harness the innovations of the American entrepreneurial ecosystem where the traditional defense firms have failed.” Biotech and the Military 
As the U.S. military looks to reshape the national security and innovation base to respond to pandemics and embrace evolving technologies such as synthetic biology, biotech has become a crucial focus area for the government. 
As stated by Dr. Will Roper, Assistant Secretary of the Air Force for Acquisition, Technology and Logistics in Breaking Defense, “There are so many breakthroughs that are happening. We don’t typically think about biology as a core competency in the Air Force, but biology teaches us a ton.” 
Second Front Systems is a public benefit corporation operating in a new class of venture-backed defense companies that includes Palantir, Anduril, and Rebellion Defense.
About Second Front Systems
Second Front Systems is a veteran-owned small business that builds software so U.S. and allied governments can harness disruptive technology from venture capital-backed, commercially proven companies. For more information visit https://secondfront.com/
About ARTIS Ventures 
ARTIS Ventures (AV) partners with entrepreneurs who are driven to impact the world by reshaping and reinventing industries. The team supports its portfolio companies through their entire life-cycle, from initial venture investment to public offering and beyond. As an early leader in the emerging TechBio sector, ARTIS Ventures funds companies at the intersection of computer science and life science, applying engineering principles and data-enabled discovery to the healthcare space. Notable companies the firm has backed include YouTube, Modern Meadow, Nimble Storage, StemCentrx, Palantir, IDbyDNA, Versa Networks, Cohesity, Locus Biosciences, Eko, Excision BioTherapeutics, Aether, Unnatural Products, Inc., and more. For more information visit www.av.co or email contact@av.co.

Continue Reading

Artificial Intelligence

DIAGNOS Announces that its Client in California, the Chaparral Medical Group of Clinics, is Reopening the Screening Services for Diabetic Retinopathy after the COVID-19 Shutdown

GlobeNewswire

Published

on

BROSSARD, Quebec, July 07, 2020 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues using advanced Artificial Intelligence (AI), is pleased to announce that its client, Chaparral Medical Group (“Chaparral”), is reopening amid additional safety extra measures being implemented to address the COVID-19 situation.
Dr. Prasad Jeereddi, MD, Diabetes Specialist, President, and Medical Director of Chaparral stated: “The remote screenings are conducted using a telemedicine application which temporarily replaces the requirement for patients to be seen in person by a specialist. It only takes 5 minutes to perform the screening test. It prevents the need for the diabetic patient to get their eyes tested in a different location. Chaparral operates 33 clinics across the state of California. Diabetic patients are vulnerable to COVID-19 and the convenience of the test in our clinic reduces the risk for COVID-19 exposure.”Telemedicine refers to the practice of caring for patients remotely when the provider and patient are not physically present with each other.Mr. Yves-Stephane Couture, vice-president of sales at DIAGNOS added: “We are pleased to provide extra service at the point of care (POC) for Chaparral’s patients. While the patient is in the clinic, it’s an excellent opportunity to check their eyes for diabetic retinopathy. Diabetes is the most common cause of vision impairment and blindness among working-age adults in the United States as per the US Centers for Disease Control and Prevention.”
About Chaparral Medical Group

Chaparral Medical Group is a multi-specialty healthcare group serving the communities of Claremont, La Verne, San Dimas, Fontana, Pomona, Rancho Cucamonga, Upland, Chino Hills and Diamond Bar in Southern California. Over 20 primary care physicians serve as the group’s clinical core, and work together with their medical and surgical specialists to provide outstanding care to the patient population of Southern California. They have been serving the community since 1978 and their unwavering commitment to patient care and physician work satisfaction are what have driven them to become the most trusted and relied-upon group of physicians in their area.

About DIAGNOS

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet and is compatible with all recognized image formats and brands of fundus cameras and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.
Additional information is available at www.diagnos.com and www.sedar.comThis news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.For further information, please contact: Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224

Continue Reading

Trending

Roboticulized is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Roboticulized digests / hand picks the latest news about the AI industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Roboticulized.com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania